JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production

Abstract

These results suggest that the JAK inhibitor tofacitinib suppresses osteoclast-mediated structural damage to arthritic joints, and this effect is secondary to decreased RANKL production.